Point72 Asia Singapore Pte. Ltd. Makes New $40,000 Investment in Carisma Therapeutics, Inc. (NASDAQ:CARM)

Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 26,006 shares of the company’s stock, valued at approximately $40,000. Point72 Asia Singapore Pte. Ltd. owned about 0.06% of Carisma Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Separately, Vanguard Group Inc. boosted its holdings in shares of Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after purchasing an additional 11,200 shares during the period. 44.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Carisma Therapeutics in a report on Wednesday, June 26th.

Carisma Therapeutics Trading Down 2.8 %

Shares of Carisma Therapeutics stock opened at $0.98 on Tuesday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.25 and a current ratio of 3.25. Carisma Therapeutics, Inc. has a fifty-two week low of $0.80 and a fifty-two week high of $4.86. The firm has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.37. The company has a market cap of $40.78 million, a P/E ratio of -0.49 and a beta of 1.50.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.09. The firm had revenue of $9.20 million for the quarter, compared to analyst estimates of $3.65 million. Carisma Therapeutics had a negative return on equity of 344.89% and a negative net margin of 350.08%. As a group, equities analysts predict that Carisma Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.